Paul Daruwala was hired last year as VP marketing at Vertex Pharmaceuticals. It's a big change from his previous job of VP marketing at Merck & Co., a big marketer. While Vertex is unknown, it's new
drug telaprevir, a treatment for hepatitis C, has won approval from regulators. Daruwala's challenge is to get the name out to consumers and caregivers.
Read the whole story at The Boston Globe »
